BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Careful Connections: Building Association and Trust - 2South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- 3A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- 4A photographer finds thousands of dinosaur footprints near Italian Winter Olympic venue
- 5Flu season is ramping up, and some experts are "pretty worried"
- Productive CRM Programming for Client Relationship The executives
- IDF drops over 80 explosives on Tehran weapon production sites in latest strike
- Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- If someone's always late, is it time blindness, or are they just being rude?
- Best Streaming Gadget for Your Home Theater
- At least 490 protesters killed in Iran, activists say
- 2026 will be the year NASA astronauts fly around the moon again — if all goes to plan
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
